Strata Appoints Will Cook to Board, Enhancing Organ Transplant Services
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: Globenewswire
- New Board Member: Strata Critical Medical has appointed Will Cook to its Board of Directors, effective December 3, 2025, aiming to leverage his extensive healthcare experience to scale the company's organ recovery and logistics platform nationwide.
- Rich Leadership Experience: Will Cook, previously President and CEO of Vail Health, brings deep industry relationships from a nonprofit community healthcare system in Colorado, which will provide invaluable resources to Strata in its mission to increase organ transplant numbers.
- Support for Strategic Development: Cook's leadership at the University of Colorado Hospital included major facility development projects, showcasing his strategic vision in healthcare services that will aid Strata in executing its multi-pronged growth strategy.
- Solid Educational Background: Will Cook holds a master's degree in health administration from Washington University School of Medicine and a Bachelor of Arts in Business Administration from Texas A&M University, further enhancing his expertise in the healthcare sector and laying a strong foundation for Strata's future growth.
Analyst Views on SRTA
Wall Street analysts forecast SRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTA is 9.25 USD with a low forecast of 7.25 USD and a high forecast of 11.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.570
Low
7.25
Averages
9.25
High
11.25
Current: 5.570
Low
7.25
Averages
9.25
High
11.25
About SRTA
Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, expanding its portfolio of services through acquisition and organic growth. The Company focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The Company also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
